ClearPoint COO settles 13,827 RSUs into shares

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin settled previously granted restricted stock units into 13,827 shares of common stock on their scheduled vesting date.

Accepted by SEC EDGAR 03/10/2026 - 04:57 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin settled previously granted restricted stock units into 13,827 shares of common stock on their scheduled vesting date. To cover tax withholding obligations, 7,036 shares were delivered back to ClearPoint Neuro. Following these compensation-related transactions, Mazin directly holds 54,523 shares of common stock.

Insider Trade Summary

13,827 shares exercised/converted

Exercise 3 txns

Insider SABRA MAZIN

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	13,827	$0.00	$0.00
Exercise	Common Stock	13,827	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	7,036	$10.00	$70K

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 54,523 shares (Direct)

Holdings Before and After: Restricted Stock Units, 13,827 to 0 contracts (Direct); Common Stock, 47,732 to 54,523 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) report for Sabra Mazin?

ClearPoint Neuro reported that COO Sabra Mazin settled restricted stock units into 13,827 shares of common stock, with a portion of those shares used to satisfy tax withholding obligations as part of routine equity compensation.

How many ClearPoint Neuro (CLPT) shares were issued from RSU vesting?

A total of 13,827 shares of ClearPoint Neuro common stock were issued upon the vesting and settlement of restricted stock units, with each unit converting into one share under the company’s equity compensation arrangement.

How many CLPT shares were withheld for taxes in this Form 4?

The filing shows that 7,036 shares of ClearPoint Neuro common stock were delivered to the company to satisfy applicable tax withholding obligations connected to the vesting of restricted stock units awarded to COO Sabra Mazin.

What is Sabra Mazin’s ClearPoint Neuro (CLPT) share ownership after these transactions?

After the RSU settlement and related tax withholding share delivery, COO Sabra Mazin directly owns 54,523 shares of ClearPoint Neuro common stock, as reported in the post-transaction holdings column of the Form 4 filing.

Were these ClearPoint Neuro (CLPT) insider transactions open-market trades?

No, the reported activity reflects settlement of restricted stock units and shares delivered for tax withholding. The Form 4 does not show any open-market purchases or sales; it records compensation-related equity vesting and associated tax-share transfers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SABRA MAZIN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		M		13,827	A	(1)	61,559	D
Common Stock	03/06/2026		F		7,036(2)	D	$10	54,523	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/06/2026		M			13,827	(1)	(1)	Common Stock	13,827	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Mazin Sabra	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.